Detection of minimal/molecular residual disease(MRD)based on ctDNA assay develops from hematological malignancies to solid tumors.Generally,there are two mainstream assays in MRD testing technology:tumor-informed and ...Detection of minimal/molecular residual disease(MRD)based on ctDNA assay develops from hematological malignancies to solid tumors.Generally,there are two mainstream assays in MRD testing technology:tumor-informed and tumor-agnostic.For colorectal cancer(CRC),MRD is used not only to monitor recurrence and predict prognosis,but also to help in clinical decision making and assessment of clinical efficacy in the settings of curative surgery,radiotherapy,chemotherapy and surveillance.Accumulated clinical trials are exploring roles of MRD in early or advanced stages of CRC.Here,we give an overview of how MRD is and will be used in CRC.展开更多
基金supported by Shenzhen Peo-ple’s Hospital Funding(grant number:SYWGSLCYJ202202)Shen-zhen Science and Technology Innovation Commission(grant num-ber:JCYJ20190807150403655)the Health,Population and Fam-ily Planning Commission of Shenzhen Municipality(grant number:SZXJ2018023).
文摘Detection of minimal/molecular residual disease(MRD)based on ctDNA assay develops from hematological malignancies to solid tumors.Generally,there are two mainstream assays in MRD testing technology:tumor-informed and tumor-agnostic.For colorectal cancer(CRC),MRD is used not only to monitor recurrence and predict prognosis,but also to help in clinical decision making and assessment of clinical efficacy in the settings of curative surgery,radiotherapy,chemotherapy and surveillance.Accumulated clinical trials are exploring roles of MRD in early or advanced stages of CRC.Here,we give an overview of how MRD is and will be used in CRC.
